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Summary
Mitochondrial diseases are characterized by considera-
ble clinical variability and are most often caused by mu-
tations in mtDNA. Because of the phenotypic variability,
epidemiological studies of the frequency of these dis-
orders have been difficult to perform. We studied the
prevalence of the mtDNA mutation at nucleotide 3243
in an adult population of 245,201 individuals. This mu-
tation is the most common molecular etiology of ME-
LAS syndrome (mitochondrial encephalomyopathy, lac-
tic acidosis, and strokelike episodes), one of the clinical
entities among the mitochondrial disorders. Patients
with diabetes mellitus, sensorineural hearing impair-
ment, epilepsy, occipital brain infarct, ophthalmoplegia,
cerebral white-matter disease, basal-ganglia calcifica-
tions, hypertrophic cardiomyopathy, or ataxia were as-
certained on the basis of defined clinical criteria and
family-history data. A total of 615 patients were
identified, and 480 samples were examined for the mu-
tation. The mutation was found in 11 pedigrees, and its
frequency was calculated to be x16.3/100,000 in the
adult population (95% confidence interval 11.3–21.4/
100,000). The mutation had arisen in the population at
least nine times, as determined by mtDNA haplotyping.
Clinical evaluation of the probands revealed a syndrome
that most frequently consisted of hearing impairment,
cognitive decline, and short stature. The high prevalence
of the common MELAS mutation in the adult popula-
tion suggests that mitochondrial disorders constitute one
of the largest diagnostic categories of neurogenetic
diseases.
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Introduction
The mitochondrial genome (mtDNA) is a double-
stranded, circular molecule of 16,569 nucleotide pairs
that is present in 2–10 copies in each mitochondrion
(Wallace 1994a; Johns 1995; Shoffner 1996; Schon et
al. 1997). This extranuclear genome is inherited mater-
nally, and it is passed from the mother to all her off-
spring. mtDNA encodes 13 of 180 subunits in the mi-
tochondrial respiratory-chain complexes, and it also
contains genes for two rRNAs and 22 tRNAs.Mutations
in mtDNA may therefore cause a respiratory-chain de-
ficiency. Tissues with a high energy expenditure—for ex-
ample, brain and muscle—suffer the most, although any
organ may be affected, thus contributing to the clinical
variability observed in mitochondrial diseases. Another
factor involved in the phenotypic heterogeneity is the
degree of mutant heteroplasmy. The normal genome and
the mutant variant coexist in cells, and a high proportion
of the mutant variant predicts a more severe clinical
expression of the disease.
The acronym “MELAS” (mitochondrial encephalo-
myopathy, lactic acidosis, and strokelike episodes [MIM
540000]) denotes the classic clinical features of one of
the mitochondrial syndromes (Pavlakis et al. 1984). Al-
though the multiorgan involvement and the phenotypic
variability of the disease make clinical diagnosis of ME-
LAS syndrome difficult, the discovery of an ArG point
mutation at nucleotide 3243 (A3243G) in the tRNALeu
gene of mtDNA (Goto et al. 1990; Mitomap) has ena-
bled a definitive diagnosis to be established. Clinical
evaluation of patients carrying this mutation has also
revealed novel features, including phenotypes such as
sensorineural hearing impairment, hypertrophic car-
diomyopathy, ataxia, basal-ganglia calcifications, and
ophthalmoplegia (Mariotti et al. 1995; Morgan-Hughes
et al. 1995), as well as the quite commonly occurring
diabetes mellitus (Kadowaki et al. 1994).
The frequency of pathogenic mtDNA mutations in a
general population is unknown, but we assume that the
prevalence of a given mutation may be estimated. Fin-
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land provides good opportunities to perform epidemi-
ological studies, since there is universal access to health
care and the inhabitants are assigned to publicly funded
health services on a regional basis. The registers available
in the health-care system represent, to a large extent, the
total morbidity in the population. We attempted to iden-
tify as many patients with the A3243G mutation as pos-
sible in the adult population of 245,201 in the province
of Northern Ostrobothnia in northern Finland. Using
various regional and municipal health-care registers, we
first identified patients with clinical disorders that are
commonly seen in association with the A3243G muta-
tion. Subgroups of patients were then ascertained by
reference to clinical criteria and family-history data and
were analyzed for the presence of the mutation. In this
way we estimated for the first time a prevalence for the
common MELAS mutation A3243G in the adult pop-
ulation, determined its frequencies in several patient
groups, and demonstrated that it has arisen indepen-
dently on several occasions in a relatively small
population.
Methods
Setting
The prevalence area considered here is Northern Os-
trobothnia, a province that extends across the northern
part of Finland, from the Gulf of Bothnia in the west to
the Russian border in the east. The area of the province
is 29,965 km2, and, administratively, it is divided into
42 local government districts, with populations of
720–106,419 (median 4,793). The total population of
the province was 353,895, and people x20 years of age
numbered 245,201 on December 31, 1994 (hereafter
termed the “prevalence date”).
Primary health care in Finland is provided by the local
authorities, and specialized medical care is provided at
the provincial level. In Northern Ostrobothnia, it isOulu
University Hospital (OUH) that provides specialized
medical care. The inhabitants are entitled to services at
this institution, and, in fact, they may seek publicly
funded medical care at institutions in other parts of the
country only if they obtain the permission of their own
local health authority. Private hospitals account for
8.4% of total hospital-care expenditure in the country,
and private practitioners account for 6.8% of all out-
patient visits in Northern Ostrobothnia (NAWH Na-
tional Research and Development Centre for Welfare
and Health 1994). This means that the files of the local
health-care units and the institutions providing special-
ized medical care provide a fairly good representation
of the prevalence of diseases in the population.
The Departments of Neurology and Cardiology at
OUH are the only centers for their disciplines in
Northern Ostrobothnia, as is the Department of Oto-
rhinolaryngology in the provision of audiological ser-
vices. Computerized discharge files are available from
1976 onward, for in-patients, and from 1984 onward,
for outpatient visits. The findings of each radiological
examination are coded, and the codes have been filed
electronically since 1980.
Identification of Patient Cohorts
Adult patients with diagnoses that are commonly as-
sociated with the A3243G mutation (Johns 1995; Shoff-
ner 1996) were defined as being at risk for a mitochon-
drial disorder. We therefore screened for patients 120
years of age who had disorders such as diabetes mellitus,
sensorineural hearing impairment, cardiomyopathy, and
brain infarct; patients 120 years of age with symptoms
such as epilepsy, ataxia, and subjective visual distur-
bance (including field defects and double vision); and
patients 120 years of age with radiological findings (in
either a brain computed-tomography scan or magnetic-
resonance imaging) such as an occipital lesion, basal-
ganglia calcifications, and cerebral white-matter lucen-
cies (table 1).
In the entire population of Northern Ostrobothnia,
the total number of patients with diabetes mellitus, sen-
sorineural hearing impairment requiring a hearing aid,
or epilepsy was 18,642. Population-based cohorts of pa-
tients with defined clinical characteristics were then iden-
tified in the appropriate registers (table 1). To minimize
screening, we assessed the family history, with respect
to any combination of diabetes mellitus, hearing loss,
and epilepsy, in first- and second-degree relatives, by
means of a questionnaire (table 1); the mean response
rate was 83%. Patients with any one or any combination
of the three disorders in maternal relatives were eligible
for inclusion within the series to be examined.
Using the discharge files of OUH, we identified 2,580
patients in the remaining six diagnostic groups. Their
medical charts were reviewed, and, by reference to the
defined criteria, they were deemed to be eligible for ex-
amination (table 1). Family history was not used as a
selection criterion for these patients.
A blood sample was requested from each patient ful-
filling the selection criteria (table 2). After the A3243G
mutation had been found, a muscle-biopsy sample or
buccal-epithelial-cell sample also was taken, and, in ad-
dition, the adult members of the families concernedwere
requested to visit the outpatient clinic, where similar
samples were obtained from those who had volunteered.
Molecular Methods
DNA from the blood samples and buccal-epithelial-
cell samples was purified by use of the QIAamp Blood
Kit (QIAGEN), and that from themuscle-biopsy samples
was purified by a standard extraction method. All the
blood samples were screened for the A3243G mutation,
Table 1
Criteria Used in Screening of Patient Groups
Patient Group Selection Criterion 1
No. of
Patients
Identified Selection Criterion 2
No. of
Patients
Identified
No. (%) of
Samples
Received
Diabetesa Insulin treatment started at age 20–45 years 479 Family history 169b 143 (85)
Hearing lossc Sensorineural hearing impairment, hearing
aid obtained at age X45 years, current
age x20 years
242 Family history 108b 82 (76)
Epilepsyd Outpatient visit to OUH, age x20 years at
visit, response to family-history
questionnaire
945 Family history 223b 165 (74)
Brain infarct Brain infarct, occipital lesion in computed-
tomography scan or visual-field defect,
age X45 years at diagnosis
823 Occipital infarct, age 20–45 years at onset 35 29 (83)
Ophthalmoplegia Double vision or ptosis, any age 799 Definite ophthalmoplegia or symmetric ptosis, age x20
years at examination
15 15 (100)
Basal-ganglia calcification Intracranial calcification, any age 635 Symmetric basal-ganglia calcification, significant size, age
x20 years at examination
10 8 (80)
White-matter disease White-matter disease not related to vascular
or demyelinating disorders or CNS radio-
therapy, age X55 years at examination
155 Significant extent, age x20 years at examination 5 5 (100)
Hypertrophic or dilated cardiomyopathy Any cardiomyopathy, unknown etiology 89 Hypertrophic cardiomyopathy, age 20–45 years at diagnosis 11 7 (64)
Ataxia Any ataxia, unknown etiology 79 Idiopathic cerebellar ataxia, age x20 years at visit 39 26 (67)
Total 4,246 615 480 (78)
a Patients with insulin-dependent diabetes mellitus obtain needles, syringes, insulin pens, and glucose sticks free of charge from the public-health-care units, and the supplies used are
recorded. These patients were identified from the records of 40 of 42 of the local-authority health-care units. The discharge diagnoses from one of the two regional hospitals in the area,
as well as the diabetes register of the other one, also were reviewed.
b Patients with any combination of diabetes, sensorineural hearing impairment, or epilepsy in first- or second-degree maternal relatives were included.
c The cost of hearing aids is completely refunded by the public health service, and they are supplied only by the Department of Otorhinolaryngology at OUH. The register of hearing
aids supplied was reviewed, on the basis of the following clinical criteria: symmetric sensorineural hearing impairment with undefined etiology; hearing impairment 130 dB (pure-tone
average of frequencies 0.5, 1, 2, and 4 kHz); a difference, between the ears, !10 dB; and use of a hearing aid at age !45 years.
d The majority of adult patients with epilepsy make regular follow-up visits at least once a year to the Outpatient Clinic of the Department of Neurology at OUH. During a 1-year
period, a physician involved in the study checked the charts of the patients visiting the clinic every day. The diagnosis of epilepsy was confirmed on this occasion, and patients receiving
regular antiepileptic medication were included. No distinction was made between the types or etiologies of epilepsy.
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Table 2
Frequency of A3243G Mutation in Patient Groups
Patient Group Family Historya
No. of Patients
Identified
No. of Samples
Evaluated
No. (%) of
Samples with
A3243G Mutation
Diabetes Diabetes 150 126 2 (1.6)
Epilepsy or hearing loss 19 17 0
Hearing loss Hearing loss 89 68 5 (7.4)
Diabetes or epilepsy 19 14 0
Epilepsy Epilepsy 114 87 1 (1.1)
Diabetes or hearing loss 109 78 0
Occipital stroke ) 35 29 2 (6.9)
Ophthalmoplegia ) 15 15 2 (13)
Intracranial calcification ) 10 8 1 (13)
White-matter disease ) 5 5 0
Hypertrophic cardiomyopathy ) 11 7 1 (14)
Ataxia ) 39 26 0
Total 615 480 14
a Denotes presence of the disorder in first- or second-degree maternal relatives of the proband. An ellipsis ()) denotes that family history
was not used as a selection criterion in the group.
by a restriction-fragment analysis. Specifically, PCR was
used to amplify a 399-bp fragment of mtDNA in 30
cycles in the presence of [35S]-dATP, a forward primer
corresponding to nucleotide positions 3153–3172, and
a reverse primer corresponding to nucleotide positions
3551–3531. The A3243G point mutation was detected
by cleavage with the restriction enzymeApaI (Kobayashi
et al. 1990). The digested samples were electrophoresed
through a 6% acrylamide gel, which was dried and au-
toradiographed at72C overnight, by means of Kodak
XAR-5 film with an intensifying screen. The film was
analyzed with a Bioimage scanner and image processing
apparatus (Millipore), with a setting that enabled the
detection of a band that differed from the background
by 6%. On average, a minimum mutant heteroplasmy
of 2% has been detectable in the restriction-fragment
analysis (Smith et al. 1997; Wong and Lam 1997). The
reproducibility of the method was controlled by includ-
ing, in each electrophoresis run, a sample with the
A3243G mutation.
PCR using allele-specific primers (Liu et al. 1997) was
used to amplify templates in situations in which a min-
imal degree of mutant heteroplasmy was assumed. The
method has a high sensitivity, and a detectable amount
of the mutant genome may be amplified in the presence
of a 10,000-fold excess of normal molecules (Liu et al.
1997). This method was used whenever the restriction-
fragment analysis using ApaI did not find the A3243G
mutation in the sample from a relative of the proband.
The amount of total DNA used as template was 1 pg,
in the case of blood cells, and 0.5 pg, in the case of
muscle or other tissue. In the presence of the mutant
genome, a PCR product was detected in a 1.5% agarose
gel electrophoresis.
A solid-phase minisequencing method (Suomalainen
et al. 1993; Tully et al. 1996) was used to determine the
degree of mutant heteroplasmy. Both a 5′-biotinylated
forward primer corresponding to nucleotide positions
3213–3232 and the reverse primer described above were
used to synthesize the primary PCR product, which was
quantified with a fluorometer (DyNAQuant; Hoefer Sci-
entific Instruments). An aliquot of 500 pg of the product
was immobilized on Dynabeads M-280 streptavidin
paramagnetic particles (Dynal) and was subjected to
minisequencing in the presence of a reverse primer cor-
responding to nucleotide positions 3263–3244 and ei-
ther [3H]-dCTP, to detect the mutant genome, or [3H]-
methyl TTP (Amersham), to detect the wild-type ge-
nome. Mutation heteroplasmy was calculated as the ra-
tio of radioactivity in the two reactions after correction
for the different specific activities of the nucleotides. A
good correlation was observed between the degree of
heteroplasmy obtained with this method and that with
the quantification of the ApaI-generated restriction frag-
ments and subsequent correction for heteroduplex for-
mation (Pearson correlation coefficient .930, ).P  .01
Genealogy and Haplogroup Analysis
The pedigrees of the probands with the A3243G mu-
tation were assessed, including all the first- and second-
degree maternal relatives and a maternal ancestor born
during the 19th century. The pedigrees were compiled
from the official population records, which contain in-
formation on births, deaths, marriages, and relocations
of the individuals.
A set of 10 primer pairs were used for PCR amplifi-
cation, to obtain 10 overlapping fragments covering the
mtDNA (Passarino et al. 1993). mtDNA haplogroups
were determined by analysis of RFLPs obtained with 14
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restriction enzymes (Torroni et al. 1996). The 22 tRNA
genes were sequenced in a dideoxy termination reaction
(AmpliTaq; Perkin-Elmer) using forward primers
corresponding to nucleotide positions 534–553,
3153–3172, 3951–3970, 5467–5488, 7392–7410,
8100–8121, 9911–9930, 10356–10380, 12095–12117,
14560–14585, and 15812–15838 and reverse primers
for nucleotide positions 1696–1677, 4508–4489, and
5917–5898. Approximately 21% of the total mtDNA
could be sequenced by use of these primers. Further-
more, the D-loop was sequenced in an automatic se-
quencer (ABI Prism; Perkin Elmer) using the for-
ward primers corresponding to nucleotide positions
15975–15994, 16449–16468, and 328–350.
Ethical Considerations
The protocol was approved by the Ethics Committee
of the Medical Faculty, University of Oulu. Permission
for the chart review was obtained from the FinnishMin-
istry of Social Affairs and Health. All the persons who
were initially contacted were patients of either OUH or
the local-authority health-care units, and they were con-
tacted with the consent of the attending physician. The
samples were studied after informed consent was ob-
tained from the patients.
Results
Prevalence of the A3243G Mutation in Adults
Prior to the present study, we were aware of five ped-
igrees with the A3243G mutation in the population of
Northern Ostrobothnia. The screening revealed a total
of 14 patients, including members of these five pedigrees
and members of five newly identified pedigrees. Eight of
the pedigrees were identified through a single proband,
and two pedigrees were identified through more than
one member. The frequency of the A3243G mutation in
the various patient groups is shown in table 2. We also
identified one additional pedigree with sensorineural
hearing impairment; but none of the affected members
fulfilled the selection criteria, and the pedigree was not
found in the screening.
There were 36 members of the sibships of the pro-
bands and 87 members of the sibships of their mothers,
constituting a cohort of 123 persons in all. If the pro-
bands are excluded, 68 of the 123 individuals were 120
years of age, and 33 of these volunteered to participate
in the study.We found the A3243Gmutation in 27 blood
samples from these sibships and also in archival tissue
samples from four members. The total number of ver-
ified mutation carriers 120 years of age who were living
in the province of Northern Ostrobothnia was 25 on
the prevalence date. Thus, the minimum estimate for the
prevalence of the A3243G mutation in the adult pop-
ulation of 245,201 in Northern Ostrobothnia is 10.2/
100,000 (95% confidence interval 6.2–14.2/100,000
[Gardner and Altman 1986]).
The first-degree maternal relatives of the verified mu-
tation carriers were then defined as obligatory carriers.
There were 36 obligatory carriers living in the province
of Northern Ostrobothnia, and 15 of them were 120
years of age on the prevalence date. Thus, the number
of verified and obligatory mutation carriers in the adult
population in Northern Ostrobothnia was taken to be
40, suggesting that the prevalence of the common ME-
LAS mutation is 16.3/100,000 (95% confidence interval
11.3–21.4/100,000). Analysis of the pedigrees, indeed,
suggested a very high frequency of the mutation among
the first-degree maternal relatives of a verified mutation
carrier, since the mutation could be found in x14 of the
17 adult siblings and in all seven mothers of the pro-
bands who were examined. Furthermore, a definite ab-
sence of the mutation was found only in one person,
since a maternal uncle of the proband in family 2 did
not have the mutation in blood, muscle, or a post-mor-
tem cerebral cortical sample, even though at least three
of his six siblings were mutation carriers.
Clinical Evaluation
Clinical evaluation of the 11 probands revealed syn-
dromic features in 9 of them and isolated ophthalmo-
plegia in 2 of them (table 3). Sensorineural hearing im-
pairment was the most common feature of the syndrome,
being found in each of the nine syndromic probands.
Only one of the probands had had symptoms since child-
hood: he had been examined for hearing impairment and
retarded growth at 13 years of age. The median value
for mutant heteroplasmy among the probands was 23%
in blood and 67% in muscle.
The presence of symptoms of mitochondrial disease
was evaluated in the 44 persons who gave a blood sam-
ple and who belonged to the sibship of either a proband
or a proband’s mother. The sensitivity of the radioactive
restriction-fragment analysis in the detection of the mu-
tation in blood DNA from clinically affected persons
was .93. Furthermore, the sibships included 32 persons
with the mutation in a tissue sample from whom a blood
DNA was available. In 30 cases the mutation was also
found in the blood DNA.
Haplogroup and Genealogy Analysis of the Pedigrees
RFLPs revealed that six probands belonged tomtDNA
haplogroup U, two to haplogroup H, two to haplogroup
T, and one to haplogroup I. Sequencing revealed differ-
ences in at least seven nucleotide sites within the 22
tRNA genes and the D-loop of the haplogroup H and
T mtDNAs. Interestingly, among the six probands be-
longing to haplogroup U, we found only four dissimilar
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Table 3
Clinical Features, Molecular Diagnostics, and Family History of Probands with A3243G mtDNA Mutation,
Identified in the Population of Northern Ostrobothnia
FAMILY SEX
AGE AT FIRST
EXAMINATIONa
(years)
AGE AT
DIAGNOSIS
(years)
MUTANT
HETEROPLASMY
(%)
CLINICAL FEATURES FAMILY HISTORYBlood Muscle
1 F 28 33 23 67 Epilepsy,b cognitive decline, hear-
ing impairment, basal-ganglia
calcifications, short stature
Hearing impairment, diabetes,
cognitive decline, epilepsy,
short stature
2 M 28 28 42 83 Epilepsy, hearing impairment,
basal-ganglia calcifications, oc-
cipital stroke,b hypertrophic
cardiomyopathy
Hearing impairment, diabetes
3 F 21 40 26 60 Hearing impairment, ataxia,
ophthalmoplegia, diabetes,
cardiomyopathyb
Diabetes
4 F 18 30 51 89 Hearing impairment,b diabetes,
cognitive decline, epilepsy, short
stature
Hearing impairment, diabetes,
short stature
5 M 48 58 14 58 Cognitive decline, short stature,
polyneuropathy
Diabetes, basal-ganglia
calcificationsb
6 F 32 31 0 38 Ophthalmoplegiab Ophthalmoplegia
7 M 13 20 39 89 Hearing impairment,b short stat-
ure, cognitive decline
Hearing impairment, diabetes,
short stature
8 F 26 46 40 72 Hearing impairmentb Hearing impairment
9 F 43 46 18 77 Hearing impairmentb Hearing impairment
10 F 24 26 6 10 Ophthalmoplegiab Ophthalmoplegia
11c F 37 37 9 31 Hearing impairment,b short stature Hearing impairment, short stature
a Performed because of a symptom that may be considered to be of mitochondrial origin.
b Symptom or disorder that led to the identification of the proband. Family 5 had been identified earlier, on the basis of the proband identified,
and another family member was ascertained to be in the group of patients with basal-ganglia calcifications.
c Identified during the present study but not in the initial screening.
sequences. Different mtDNA genotypes in at least nine
of the pedigrees suggest that the mutation has arisen in
the population several times.
A maternal ancestor was identified in each pedigree
(two to four generations from the proband), the median
year of birth being 1873 (range 1808–94). Three of the
11 maternal ancestors had been born in Northern Os-
trobothnia, and, interestingly, 6 of them had been born
in a much smaller population in northeastern Finland
including the province of Kainuu; of these 6 ancestors,
4, including the 3 with identical mtDNA genotypes, be-
longed to haplogroup U. Indeed, two of these pedigrees
were found to have a common ancestor born in 1864.
Genealogical analysis extending to the years 1808 and
1837 did not, however, reveal any ancestors common to
both this pedigree and the third pedigree sharing the
mtDNA genotype.
Discussion
This is the first assessment of the epidemiology of
mitochondrial diseases. We found a prevalence of
x10.2/100,000 for the A3243G mutation in the adult
population—or, if it is assumed that all the first-degree
maternal relatives of a verified mutation carrier also har-
bored the mutation, a prevalence of x16.3/100,000.
The analysis of the pedigrees suggested that this was a
reasonable approach, since the frequency of the muta-
tion was found to be very high among the first-degree
maternal relatives of the probands and only one ex-
amined relative was definitely without the mutation. The
high prevalence suggests that mitochondrial disorders
may constitute one of the largest diagnostic categories
of neurogenetic diseases among adults.
The observed prevalence represents a minimum esti-
mate for the frequency of the A3243G mutation, for
several reasons. Second-degree maternal relatives were
not considered obligatory mutation carriers even in the
presence of a family history suggesting mitochondrial
disease such as diabetes mellitus or sensorineural hearing
impairment. Cases were lost during the process of pa-
tient identification, because of nonresponse to inquiries
concerning family history, nonrecovery of patient charts
for review, and nonparticipation in blood-sample col-
lection. Furthermore, the mutation was detected in the
blood samples of the affected persons, with a sensitivity
of .93. The patient groups studied represent the clinical
phenotypes known to be associated with the A3243G
mutation, and only adult patients were identified. For
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example, pigmentary retinopathy was considered a non-
contributory phenotype when the study was initiated.
However, a recent analysis of four pedigrees suggests
that the frequency of this phenotype may be high among
patients with the A3243G mutation (Sue et al. 1997).
Children were not ascertained in this study, and, there-
fore, we may have lost pedigrees with exclusively pe-
diatric cases. The effect of these biases is parallel, and
accounting for them would increase the prevalence.
The clinical phenotype of the ascertained probands
suggested a multiorgan disorder in nine cases, most fre-
quently including sensorineural hearing loss, cognitive
decline, or short stature. We observed isolated ophthal-
moplegia in two probands, and ocular symptoms alone
were reported in other members of both families. Inter-
estingly, no cases with childhood-onset classic MELAS
syndrome (Pavlakis et al. 1984) could be found either
among the probands themselves or among the 59 chil-
dren of either the female probands or the sisters of the
probands. These results suggest either that the mutation
may cause lower morbidity in children than in adults or
that childhood cases and adult cases do not occur con-
currently in families.
A frequency of 0.9% for the A3243G mutation has
been observed in unselected patients with diabetes
(Maassen and Kadowaki 1996). The corresponding rate
in the present study was 0.5%, whereas the frequency
among the patients with matrilinear diabetes was 1.6%.
Similar ratios, in the range of 2.0%–5.5%, have been
reported among patients with familial diabetes (Gerbitz
et al. 1995; Maassen and Kadowaki 1996). The mini-
mum frequency of the mutation among unselected adult
patients with hearing loss requiring a hearing aid was
0.07%, whereas that in the selected cohort of patients
with matrilinear sensorineural hearing loss was 7%, sug-
gesting that the mutation is more frequent among these
patients than among patients with matrilinear diabetes
mellitus (Gerbitz et al. 1995; Maassen and Kadowaki
1996). We found mutation frequencies on the order of
10% among patients with ophthalmoplegia or hyper-
trophic cardiomyopathy. Previously, no etiology had
been identified in the patients selected for the mutation
analysis, in either group. These data suggest that a search
for an mtDNA mutation is worthwhile in the diagnosis
of young patients with these disorders. The frequency
of the mutation was also fairly high among young pa-
tients with an occipital brain infarct (Majamaa et al.
1997).
RFLPs and the tRNA and D-loop sequences of the 11
probands revealed nine distinct mtDNA genotypes, sug-
gesting that the mutation had arisen in the population
several times. A similar finding, based on the variability
of nucleotides in the D-loop, has been reported for the
A3243G mutation (Morten et al. 1995) and for the
A1555G mutation (Hutchin and Cortopassi 1997). We
found an apparent clustering in haplogroup U, since six
probands belonged to this haplogroup. Three of these
six had an identical mtDNA genotype, however, and two
of them were found to be distant maternal relatives.
The maternal ancestors, whose median year of birth
was 1873, were mainly of northeastern Finnish descent.
Of the 10 families, 5 originated from the province of
Kainuu and the easternmost district of Northern Ostro-
bothnia, an area with a total population of 55,593 in
the year 1900, whereas 3 families originated from the
remaining part of Northern Ostrobothnia, an area with
a population of 170,424 in 1900. These figures suggest
that the frequency of families with the A3243Gmutation
may have been x5.1-fold higher in Kainuu than in
Northern Ostrobothnia. This is interesting in view of the
fact that the province of Kainuu did not belong to the
area from which the initial population for this survey
was taken.
Finland is known for 130 heritable disorders that are
more prevalent there than in other countries (Norio et
al. 1973; de la Chapelle 1993; Peltonen et al. 1995), and
the concept of a Finnish disease heritage has been used
to describe this phenomenon (Norio et al. 1973). The
clustering of diseases is due partly to the founder effect
and partly to the Finnish population’s isolation because
of geographical, linguistic, and cultural reasons. We
found that the A3243Gmutation in mtDNAmay be one
of the most common single mutations among neuroge-
netic diseases in the adult Finnish population. That we
encountered a cluster of the A3243G mutation within
the country is unlikely, since our preliminary results sug-
gest that the average frequency of the mutation is similar
in the provinces of Central Ostrobothnia and Kainuu
(authors’ unpublished observations). In the absence of
other studies of the epidemiology of mitochondrial dis-
orders, we are not able to assess whether the mutation
is part of the Finnish disease heritage or whether its
frequency is similar to that in other populations. The
former alternative may be true if nuclear mutations are
required to provoke mtDNA mutations; the latter may
be true if only a constant rate of new mutations in
mtDNA is involved.
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